YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Fundamental Analysis
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Fundamental Analysis
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) shows weak financial fundamentals with a PE ratio of 24.96, profit margin of 12.96%, and ROE of 5.87%. The company generates $3.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 50.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 1558.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1558.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent1558.HK trades at attractive valuation levels.
Growth Score
Moderate1558.HK shows steady but slowing expansion.
Financial Health Score
Excellent1558.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1558.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1558.HK Expensive or Cheap?
P/E Ratio
1558.HK trades at 24.96 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 1558.HK's PEG of 0.29 indicates potential undervaluation.
Price to Book
The market values YiChang HEC ChangJiang Pharmaceutical Co., Ltd. at 1.42 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.70 times EBITDA. This signals the market has high growth expectations.
How Well Does 1558.HK Make Money?
Net Profit Margin
For every $100 in sales, YiChang HEC ChangJiang Pharmaceutical Co., Ltd. keeps $12.96 as profit after all expenses.
Operating Margin
Core operations generate 18.11 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.87 in profit for every $100 of shareholder equity.
ROA
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. generates $3.88 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. generates limited operating cash flow of $89.42M, signaling weaker underlying cash strength.
Free Cash Flow
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. generates weak or negative free cash flow of $-1.09B, restricting financial flexibility.
FCF Per Share
Each share generates $-1.24 in free cash annually.
FCF Yield
1558.HK converts -9.05% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
24.96
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.29
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.42
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.24
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.26
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.77
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How 1558.HK Stacks Against Its Sector Peers
| Metric | 1558.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 24.96 | 29.60 | Better (Cheaper) |
| ROE | 5.87% | 418.00% | Weak |
| Net Margin | 12.96% | -11442.00% (disorted) | Strong |
| Debt/Equity | 0.26 | 0.78 | Strong (Low Leverage) |
| Current Ratio | 1.77 | 5.13 | Neutral |
| ROA | 3.88% | -74.00% (disorted) | Weak |
1558.HK outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation